Puzzling higher AstraZeneca vaccine efficacy for smaller dosage explained: It was reportedly tested on people only under 56 | WHAT REALLY HAPPENED

Puzzling higher AstraZeneca vaccine efficacy for smaller dosage explained: It was reportedly tested on people only under 56

On Monday, the pharmacological company announced that its AZD1222 vaccine for Covid-19, which is based on a common cold virus that causes infection in chimpanzees, has an efficacy of 70 percent. The number is average for two slightly different tests. One involved people, who received half a dose of the vaccine, followed by a full dose a month later, while the larger second group took full doses for both shots.

Counterintuitively, the first regimen showed 90 percent efficacy, compared to 62 percent for the second group of subjects.

A larger dosage usually produces a stronger immune response, so the discrepancy made some experts wonder. Apparently, AstraZeneca omitted a key detail of their study that explains the results, Bloomberg reported on Tuesday citing Moncef Slaou, the head of the US Operation Warp Speed program.

The half-dose variant was tested on people aged between 18 and 55, while the full-dose test included elderly people.

Comments

SHARE THIS ARTICLE WITH YOUR SOCIAL MEDIA